Linvoseltamab Promising in High-Risk Smoldering Multiple Myeloma



(MedPage Today) — TORONTO — Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data.
With a median follow-up of 3.9 months among 19 evaluable…



Source link : https://www.medpagetoday.com/meetingcoverage/ims/117570

Author :

Publish date : 2025-09-20 18:53:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version